首页> 外文期刊>Clinical nuclear medicine >Metastatic Poorly Differentiated Prostatic Carcinoma With Neuroendocrine Differentiation Negative on Ga-68-PSMA PET/CT
【24h】

Metastatic Poorly Differentiated Prostatic Carcinoma With Neuroendocrine Differentiation Negative on Ga-68-PSMA PET/CT

机译:Ga-68-PSMA PET / CT上转移性低分化前列腺癌伴神经内分泌分化阴性

获取原文
获取原文并翻译 | 示例
           

摘要

Glu-NH-CO-NH-Lys-(Ahx)-[Ga-68(HBED-CC)], abbreviated as Ga-68-PSMA, is a novel radiotracer undergoing evaluation for PET/CT imaging of prostate carcinoma. Its major advantage is the sensitive detection of lesions even at low prostate-specific antigen level and high target-to-background ratios obtained in metastatic lesions, which is better than that obtained with F-18-fluoromethylcholine. We present the case of a 28-year-old man with poorly differentiated prostate carcinoma with neuroendocrine differentiation, whose lesions did not show significant Ga-68-PSMA localization. As literature on utility of Ga-68-PSMA PET/CT for imaging prostate carcinoma grows, it is important to be aware of potential false negatives that could influence study results.
机译:Glu-NH-CO-NH-Lys-(Ahx)-[Ga-68(HBED-CC)],缩写为Ga-68-PSMA,是一种新型放射性示踪剂,正在接受前列腺癌PET / CT成像评估。它的主要优点是即使在前列腺特异性抗原水平低和转移性病变中获得的靶与背景比率高的情况下,也能灵敏地检测病变,这比用F-18-氟甲基胆碱获得的更好。我们介绍了一个案例,该例为一名分化不良的前列腺癌伴神经内分泌分化的28岁男性,其病变未显示出明显的Ga-68-PSMA定位。随着Ga-68-PSMA PET / CT在前列腺癌成像中的实用性文献不断增长,重要的是要意识到可能影响研究结果的潜在假阴性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号